Sustained PGC-1α2 or PGC-1α3 expression induces astrocyte dysfunction and degeneration

Area of Science:

• Neuroscience
• Molecular Biology
• Metabolism

Background:

• Peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) transcriptional coactivators regulate energy metabolism genes.
• Different PGC-1α variants exist with distinct tissue-specific functions.
• The role of PGC-1α isoforms in the brain, particularly in Parkinson's disease (PD), is underexplored.

Purpose of the Study:

• To investigate the role of PGC-1α isoforms in the nigrostriatal pathway during Parkinson's disease pathogenesis.
• To determine the impact of PGC-1α isoforms on astrocyte reactivity and astrogliosis.
• To identify cellular pathways modulated by PGC-1α isoforms in reactive astrocytes.

Main Methods:

• Utilized a toxin-based mouse model of Parkinson's disease (MPTP model).
• Analyzed PGC-1α variant expression in the nigrostriatal pathway.
• Performed transcriptome analysis (RNA-seq) of astrocytes expressing PGC-1α isoforms (1α1-1α4).

Main Results:

• PGC-1α2 and PGC-1α3 expression increased in the nigrostriatal pathway during dopaminergic cell degeneration.
• These increases correlated with elevated glial fibrillary acidic protein levels.
• PGC-1α2 and PGC-1α3 altered inflammatory, antioxidant, adhesion, migration, and viability pathways in reactive astrocytes, leading to dysfunction and degeneration.

Conclusions:

• PGC-1α isoforms, specifically PGC-1α2 and PGC-1α3, modulate astrocyte reactivity.
• Sustained expression of PGC-1α2 and PGC-1α3 induces astrocyte dysfunction and degeneration.
• PGC-1α isoforms represent potential therapeutic targets for Parkinson's disease and other neurodegenerative disorders.